JP6549126B2 - 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット - Google Patents

生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット Download PDF

Info

Publication number
JP6549126B2
JP6549126B2 JP2016539674A JP2016539674A JP6549126B2 JP 6549126 B2 JP6549126 B2 JP 6549126B2 JP 2016539674 A JP2016539674 A JP 2016539674A JP 2016539674 A JP2016539674 A JP 2016539674A JP 6549126 B2 JP6549126 B2 JP 6549126B2
Authority
JP
Japan
Prior art keywords
mvp
solution
protein
binding
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016539674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529908A5 (enExample
JP2016529908A (ja
Inventor
デイビッド セトリン，
デイビッド セトリン，
アルン ダール，
アルン ダール，
Original Assignee
モックヴィー ソリューションズ， インコーポレイテッド
モックヴィー ソリューションズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モックヴィー ソリューションズ， インコーポレイテッド, モックヴィー ソリューションズ， インコーポレイテッド filed Critical モックヴィー ソリューションズ， インコーポレイテッド
Publication of JP2016529908A publication Critical patent/JP2016529908A/ja
Publication of JP2016529908A5 publication Critical patent/JP2016529908A5/ja
Application granted granted Critical
Publication of JP6549126B2 publication Critical patent/JP6549126B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/015—Parvoviridae, e.g. feline panleukopenia virus, human Parvovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016539674A 2013-09-10 2014-09-09 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット Active JP6549126B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361875729P 2013-09-10 2013-09-10
US61/875,729 2013-09-10
PCT/IB2014/064352 WO2015036917A2 (en) 2013-09-10 2014-09-09 Methods and kits for quantifying the removal of mock virus particles from a purified solution

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019118216A Division JP2019195333A (ja) 2013-09-10 2019-06-26 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット

Publications (3)

Publication Number Publication Date
JP2016529908A JP2016529908A (ja) 2016-09-29
JP2016529908A5 JP2016529908A5 (enExample) 2017-11-16
JP6549126B2 true JP6549126B2 (ja) 2019-07-31

Family

ID=52625972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016539674A Active JP6549126B2 (ja) 2013-09-10 2014-09-09 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット
JP2019118216A Withdrawn JP2019195333A (ja) 2013-09-10 2019-06-26 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019118216A Withdrawn JP2019195333A (ja) 2013-09-10 2019-06-26 生成された溶液からのモックウイルス粒子の除去を定量するための方法およびキット

Country Status (7)

Country Link
US (4) US9632087B2 (enExample)
EP (1) EP3044339B1 (enExample)
JP (2) JP6549126B2 (enExample)
CN (1) CN105899684B (enExample)
AU (3) AU2014320015B2 (enExample)
DK (1) DK3044339T3 (enExample)
WO (1) WO2015036917A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3044339T3 (da) * 2013-09-10 2019-08-12 MockV Solutions Fremgangsmåder og sæt til kvantificering af fjernelsen af falske (MOCK) viruspartikler fra en renset opløsning
WO2020100957A1 (ja) * 2018-11-14 2020-05-22 日産化学株式会社 生体材料の保存、前処理、分析のための容器及び方法
JP7390466B2 (ja) * 2020-02-28 2023-12-01 旭化成メディカル株式会社 ウイルスクリアランス性能の評価方法
US12203914B2 (en) 2020-11-12 2025-01-21 Sartorius Bioanalytical Instruments, Inc. Viral clearance evaluation for biological medical product preparation processes
CN118465260B (zh) * 2024-07-09 2024-10-15 浙江康佰裕生物科技有限公司 测定逆转录病毒包膜蛋白elisa方法的建立及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01503675A (ja) * 1986-09-08 1989-12-14 アプライド・バイオテクノロジー・インコーポレーテツド 中空ウイルスキヤプシドのワクチン
US5173399A (en) * 1988-06-10 1992-12-22 Abbott Laboratories Mouse monoclonal antibodies to hiv-1p24 and their use in diagnostic tests
CA2002839C (en) * 1988-11-14 2000-10-10 Neal S. Young Parvovirus capsids
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
US5814442A (en) * 1994-06-10 1998-09-29 Georgetown University Internally controlled virion nucleic acid amplification reaction for quantitation of virion and virion nucleic acid
US7122645B2 (en) 2000-03-27 2006-10-17 Smithkline Beecham Corporation Detection of viable agents
EP2365082A1 (en) * 2000-06-27 2011-09-14 Pfizer Animal Health S.A. BVDV virus-like particles
US20040002058A1 (en) * 2001-06-21 2004-01-01 Uab Research Foundation Chimeric capsid proteins and uses thereof
US7041444B2 (en) * 2003-01-14 2006-05-09 Washington University Murine calicivirus
WO2005023313A1 (en) * 2003-09-09 2005-03-17 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to hiv humans
EP1973608A1 (en) * 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US20100297604A1 (en) * 2006-06-09 2010-11-25 Xing-Xiang Li Methods and reagents for virus isolation and detection
WO2008036899A2 (en) * 2006-09-22 2008-03-27 Amgen Inc. Methods for removing viral contaminants during protein purification
JP5710254B2 (ja) * 2007-09-14 2015-04-30 アンスティテュ・パストゥールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ 外来エピトープを含む組換え偽ウイルスの発現および分泌を可能とするポリヌクレオチド、それらの製造および使用
GB0803068D0 (en) * 2008-02-20 2008-03-26 Health Prot Agency Cross-linked biological indicator
NZ592097A (en) * 2008-10-20 2013-01-25 Abbott Lab Viral inactivation during purification of il-12 and il-18 antibodies
US9744228B2 (en) * 2010-04-07 2017-08-29 Norvartis Ag Method for generating a parvovirus B19 virus-like particle
BR112012026095A2 (pt) * 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
DK3044339T3 (da) * 2013-09-10 2019-08-12 MockV Solutions Fremgangsmåder og sæt til kvantificering af fjernelsen af falske (MOCK) viruspartikler fra en renset opløsning

Also Published As

Publication number Publication date
EP3044339A2 (en) 2016-07-20
US20190353656A1 (en) 2019-11-21
US20150072339A1 (en) 2015-03-12
EP3044339B1 (en) 2019-05-22
WO2015036917A2 (en) 2015-03-19
CN105899684B (zh) 2021-06-11
AU2014320015A1 (en) 2016-03-31
AU2014320015B2 (en) 2020-10-29
CN105899684A (zh) 2016-08-24
US11754565B2 (en) 2023-09-12
US10309963B2 (en) 2019-06-04
AU2023229501A1 (en) 2023-09-28
EP3044339A4 (en) 2017-04-26
AU2021200484B2 (en) 2023-06-29
AU2023229501B2 (en) 2025-04-03
WO2015036917A3 (en) 2015-12-03
JP2016529908A (ja) 2016-09-29
US9632087B2 (en) 2017-04-25
JP2019195333A (ja) 2019-11-14
US20240085419A1 (en) 2024-03-14
AU2021200484A1 (en) 2021-02-25
US20170192001A1 (en) 2017-07-06
DK3044339T3 (da) 2019-08-12

Similar Documents

Publication Publication Date Title
US20240085419A1 (en) Methods and kits for quantifying the removal of mock virus particles from a purified solution
Tustian et al. Assessment of quality attributes for adeno‐associated viral vectors
TWI735433B (zh) 偵測生物污染物之組成物及方法
CN110105436B (zh) 猪圆环病毒3型抗体的elisa检测试剂盒及其制备方法与应用
JP2016523812A (ja) タンパク質のピログルタミン酸形成を増加させるための方法
JP2537850B2 (ja) レトロウイルスを含まぬ免疫グロブリンの製法
JP2016529908A5 (enExample)
CN109111507B (zh) 病毒重组糖蛋白及其真核细胞高效表达方法与应用
WO2022262206A1 (zh) Gmp级逆转录病毒载体的纯化方法与应用
Krishnan et al. Purification and functional characterization of a biologically active full-length feline immunodeficiency virus (FIV) Pr50Gag
CN105861530B (zh) 承载GAD65 p271-284肽段的I-Ag7果蝇细胞高表达基因序列和构建的Tetramer
CN117903300A (zh) 一种a型口蹄疫病毒中和抗体hy1及其制备方法与应用
Xiao et al. Enhanced expression of GCRV VP6 in CIK cells by relative sequence optimization
CN119039427B (zh) 一株绵羊抗蓝舌病毒的重组单个b细胞抗体
CN120737193B (en) Monoclonal antibody of anti-Oya virus nucleocapsid protein or antigen binding fragment thereof and application thereof
CN119798382B (zh) 一种人乳头瘤病毒16型突变型e2蛋白及其应用
WO2023231149A1 (en) Recombinant orthohepevirus genotype c1 orf2 protein and preparation method therefor and use thereof
EP3250696B1 (en) Stock solution of retrovirus like particles with method
Eilts Picking The Best Virus Sample Prep Method In Process Development
CN118853595A (zh) 脱脚病病毒和小鼠腺病毒假病毒制备方法及其在分子检测中的应用
CN118638825A (zh) 一种多重鼠源rna假病毒、制备方法及其应用
CN119842809A (zh) 一种hpv中和抗体假病毒及其制备方法和应用
Peetermans Quality Control of Vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190626

R150 Certificate of patent or registration of utility model

Ref document number: 6549126

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250